Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AMERICAN REGENT, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1967-01-01

Employees: 501

Market Cap: -

Website: http://www.americanregent.com

Clinical Trials

Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Ketorolac tromethamine

First Posted Date: 2011-06-03

Last Posted Date: 2013-02-06

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 30

Registration Number: NCT01365624

Locations: 🇺🇸
Seaview Research, Miami, Florida, United States

Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain

Phase 2

Completed

Conditions: Postoperative Pain

Interventions: Drug: Ketorolac tromethamine
Drug: Placebo

First Posted Date: 2011-05-10

Last Posted Date: 2012-10-18

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 127

Registration Number: NCT01351090

Locations: 🇳🇿
Waikato Clinical Research, Hamilton, New Zealand

Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding

Phase 2

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Iron Dextran Injection
Drug: Ferric Carboxymaltose (FCM)

First Posted Date: 2011-03-02

Last Posted Date: 2018-02-19

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 69

Registration Number: NCT01307007

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Phase 2

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferric Carboxymaltose (FCM)
Drug: Iron Sucrose / Iron Dextran

First Posted Date: 2011-02-07

Last Posted Date: 2018-02-08

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 49

Registration Number: NCT01290315

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1

Completed

Conditions: Myelofibrosis
Myelodysplastic Syndrome
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia

Interventions: Drug: Luitpold Azacitidine
Drug: Vidaza®

First Posted Date: 2011-02-07

Last Posted Date: 2025-06-12

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 38

Registration Number: NCT01290302

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)

Phase 4

Withdrawn

Conditions: Iron Deficiency Anemia

First Posted Date: 2010-06-28

Last Posted Date: 2018-01-24

Lead Sponsor: American Regent, Inc.

Registration Number: NCT01151592

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

Phase 3

Completed

Conditions: Iron Deficiency Anemia
Impaired Renal Function

Interventions: Drug: Ferric Carboxymaltose (FCM)
Drug: Iron Sucrose (Venofer)

First Posted Date: 2009-09-22

Last Posted Date: 2018-02-20

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 2561

Registration Number: NCT00981045

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferric Carboxymaltose (FCM)
Drug: Ferrous Sulfate Tablets
Drug: IV Iron (standard of care)

First Posted Date: 2009-09-22

Last Posted Date: 2018-02-20

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 997

Registration Number: NCT00982007

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments

Phase 2

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Cohort I
Drug: Cohort II
Drug: Cohort III

First Posted Date: 2009-05-08

Last Posted Date: 2024-11-07

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 21

Registration Number: NCT00895232

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: VIT-45
Drug: Placebo

First Posted Date: 2008-08-22

Last Posted Date: 2025-04-18

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 594

Registration Number: NCT00740246

Locations: 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy